These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 30465278

  • 1. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
    Guo L, Zhang M, Hu M, Wang B, Wang J, Zuo L, Yang W, Liu B, Liu L.
    Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
    [Abstract] [Full Text] [Related]

  • 2. Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.
    Srinivasan NT, Patel KH, Qamar K, Taylor A, Bacà M, Providência R, Tome-Esteban M, Elliott PM, Lambiase PD.
    Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408651
    [Abstract] [Full Text] [Related]

  • 3. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N, Olivotto I, Olde Nordkamp LR, Baldini K, Fumagalli C, Brouwer TF, Knops RE, Cecchi F.
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [Abstract] [Full Text] [Related]

  • 5. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
    Randles DA, Hawkins NM, Shaw M, Patwala AY, Pettit SJ, Wright DJ.
    Europace; 2014 Jul; 16(7):1015-21. PubMed ID: 24351884
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873684
    [Abstract] [Full Text] [Related]

  • 7. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
    Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, de Groot JR, Rosenmöller BRAM, Wilde AAM, Knops RE.
    J Cardiovasc Electrophysiol; 2014 May 12; 25(5):494-499. PubMed ID: 24320684
    [Abstract] [Full Text] [Related]

  • 8. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
    Campbell M, Moore JP, Sreeram N, von Alvensleben JC, Shah A, Batra A, Law I, Sanatani S, Thomas V, Nik-Ahd F, Williams S, Nosavan N, Maldonado J, Hart A, Nguyen T, Balaji S.
    Heart Rhythm; 2018 May 12; 15(5):703-707. PubMed ID: 29309839
    [Abstract] [Full Text] [Related]

  • 9. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 12; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 10. Conventional and alternative preimplantation ECG screening for subcutaneous ICD in high risk hypertrophic cardiomyopathy patients.
    Kaczmarek K, Kałowski M, Krzysztof Wranicz J, Ptaszyńsk P, Cygankiewicz I.
    J Electrocardiol; 2020 Jul 12; 58():68-73. PubMed ID: 31770668
    [Abstract] [Full Text] [Related]

  • 11. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease.
    Wang L, Javadekar N, Rajagopalan A, Rogovoy NM, Haq KT, Broberg CS, Tereshchenko LG.
    Heart Rhythm; 2020 May 12; 17(5 Pt B):860-869. PubMed ID: 32354451
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
    Lambiase PD, Gold MR, Hood M, Boersma L, Theuns DAMJ, Burke MC, Weiss R, Russo AM, Kääb S, Knight BP.
    Heart Rhythm; 2016 May 12; 13(5):1066-1074. PubMed ID: 26767422
    [Abstract] [Full Text] [Related]

  • 13. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
    Dinshaw L, Münch J, Dickow J, Lezius S, Willems S, Hoffmann BA, Patten M.
    Clin Res Cardiol; 2018 Feb 12; 107(2):130-137. PubMed ID: 28965260
    [Abstract] [Full Text] [Related]

  • 14. Impact of routine right parasternal electrocardiographic screening in assessing eligibility for subcutaneous implantable cardioverter-defibrillator.
    Arias MA, Pachón M, Sánchez-Iglesias I, Loughlin G, Martín-Sierra C, Puchol A, Sabatel F, Rodríguez-Padial L.
    J Cardiovasc Electrophysiol; 2020 Jan 12; 31(1):103-111. PubMed ID: 31724763
    [Abstract] [Full Text] [Related]

  • 15. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA, Sharma S, Pelchovitz DJ, Bhave PD, Rhyner J, Verma N, Arora R, Chicos AB, Kim SS, Lin AC, Passman RS, Knight BP.
    Heart Rhythm; 2014 Aug 12; 11(8):1361-6. PubMed ID: 24755323
    [Abstract] [Full Text] [Related]

  • 16. The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator.
    Thomas JA, Perez-Alday EA, Hamilton C, Kabir MM, Park EA, Tereshchenko LG.
    Comput Biol Med; 2018 Nov 01; 102():242-250. PubMed ID: 29754992
    [Abstract] [Full Text] [Related]

  • 17. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr 01; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

  • 18. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 19. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE, Wu MS, Kennel PJ, Thomas G, Liu CF, Cheung JW, Markowitz SM, Lerman BB.
    J Cardiovasc Electrophysiol; 2017 May 01; 28(5):544-548. PubMed ID: 28185354
    [Abstract] [Full Text] [Related]

  • 20. Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome.
    Tachibana M, Nishii N, Morita H, Nakagawa K, Watanabe A, Nakamura K, Ito H.
    J Cardiovasc Electrophysiol; 2017 Dec 01; 28(12):1454-1459. PubMed ID: 28800177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.